-
公开(公告)号:NO972017A
公开(公告)日:1997-04-30
申请号:NO972017
申请日:1997-04-30
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: SIPIDO VICTOR KAREL , FERNANDEZ-GADEA FRANCISCO JAVI , ANDRES-GIL JOSE IGNACIO , MEERT THEO FRANS , GIL-LOPETEGUI PILAR
IPC: A61K31/535 , A61K31/55 , A61P9/00 , A61P25/00 , A61P25/18 , A61P25/24 , A61P25/26 , C07D223/20 , C07D223/30 , C07D261/00 , C07D498/04
CPC classification number: C07D223/20
-
公开(公告)号:CA2203661A1
公开(公告)日:1996-05-17
申请号:CA2203661
申请日:1995-10-25
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: FERNANDEZ-GADEA FRANCISCO JAVI , SIPIDO VICTOR KAREL , ANDRES-GIL JOSE IGNACIO , MEERT THEO FRANS , GIL-LOPETEGUI PILAR
IPC: A61K31/535 , A61K31/55 , A61P9/00 , A61P25/00 , A61P25/18 , A61P25/24 , A61P25/26 , C07D223/20 , C07D223/30 , C07D261/00 , C07D498/04 , C07D491/113 , C07D223/18 , C07D498/20
Abstract: This invention concerns the compounds of formula (I), the pharmaceutically acceptable salts and stereoisomeric forms thereof, and also the N-oxide forms thereof. In formula (I) R1 and R2 each independently are hydrogen; C1-6alkyl; C1-6alkylcarbonyl; trihalomethylcarbonyl; C1-6alkyl substituted with hydroxy, C1-6alkyloxy, carboxyl, C1-6alkylcarbonyloxy, C1-6alkyloxycarbonyl or aryl; or R1 and R2 taken together with the nitrogen atom to which they are attached may form a morpholinyl ring or an optionally substitued heterocycle; R3, R4, R5, R6, R9, R10, R11 or R12 each independently are hydrogen, halo, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, carboxyl, nitro, amino, mono- or di(C16alkyl)-amino, C1-6alkylcarbonylamino, aminosulfonyl, mono- or di(C1-6alkyl)-aminosulfonyl, C1-6alkyl, C1-6alkyloxy, C1-6alkylcarbonyl, C1-6alkyloxy-carbonyl; R7 and R8 are each independently hydrogen, hydroxy, C1-6alkyl, C16alkyloxy or R7 and R8 taken together may form mono- or di(cyano)methylene, or together with the carbon atom to which they are attached form a carbonyl or a spiro substituent; or R7 and R8 taken together may form methylene; R13 is hydrogen, C1-6alkyl, or trifluoromethyl; R14 is hydrogen, C1-6alkyl, cyano, or trifluoromethyl; n is zero to 6. These compounds were tested as mCPPantagonists in rats. The compounds of formula (I) may be used as therapeutic agents in the treatment or the prevention of CNS disorders, cardiovascular disorders or gastrointestinal disorders.
-
公开(公告)号:IL115819D0
公开(公告)日:1996-01-19
申请号:IL11581995
申请日:1995-10-31
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: FERNANDEZ-GADEA FRANCISCO JAVI , SIPIDO VICTOR KAREL , ANDRES-GIL JOSE IGNACIO , MEERT THEO FRANS , GIL-LOPETEGUI PILAR
IPC: A61K31/535 , A61K31/55 , A61P9/00 , A61P25/00 , A61P25/18 , A61P25/24 , A61P25/26 , C07D223/20 , C07D223/30 , C07D261/00 , C07D498/04 , C07D
Abstract: This invention concerns the compounds of formula (I), the pharmaceutically acceptable salts and stereoisomeric forms thereof, and also the N-oxide forms thereof. (I) wherein: R1 and R2 each independently are hydrogen; C1-6alkyl; C1-6alkylcarbonyl; trihalomethylcarbonyl; C1-6alkyl substituted with hydroxy, C1-6alkyloxy, carboxyl, C1-6alkylcarbonyloxy, C1-6alkyloxycarbonyl or aryl; or R1 and R2 taken together with the nitrogen atom to which they are attached may form a morpholinyl ring or an optionally substituted heterocycle; R3, R4, R5, R6, R9, R10, R11 or R12 each independently are hydrogen, halo, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, carboxyl, nitro, amino, mono- or di(C1-6alkyl)-amino, C1-6alkylcarbonylamino, aminosulfonyl, mono- or di(C1-6alkyl)-aminosulfonyl, C1-6alkyl, C1-6alkyloxy, C1-6alkylcarbonyl, C1-6alkyloxy-carbonyl; R7 and R8 are each independently hydrogen, hydroxy, C1-6alkyl, C1-6alkyloxy or R7 and R8 taken together may form mono- or di(cyano)methylene, or together with the carbon atom to which they are attached form a carbonyl or a spiro substituent; or R7 and R8 taken together may form methylene; R13 is hydrogen, C1-6alkyl, or trifluoromethyl; R14 is hydrogen, C1-6alkyl, cyano, or trifluoromethyl; n is zero to 6. These compounds were tested as mCPP-antagonists in rats. The compounds of formula (I) may be used as therapeutic agents in the treatment or the prevention of CNS disorders, cardiovascular disorders or gastrointestinal disorders.
-
公开(公告)号:HU225161B1
公开(公告)日:2006-07-28
申请号:HU0003748
申请日:1998-10-06
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: ANDRES-GIL JOSE IGNACIO , FERNANDEZ-GADEA FRANCISCO JAVI , GIL-LOPETEGUI PILAR , DIAZ-MARTINEZ ADOLFO
IPC: C07D307/93 , A61K31/34 , A61K31/343 , A61K31/4427 , A61K31/443 , A61K31/445 , A61K31/4525 , A61K31/495 , A61K31/496 , A61K31/535 , A61K31/5377 , A61K31/55 , A61P25/00 , A61P25/06 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/30 , C07D401/06 , C07D405/06 , C07D493/04
Abstract: This invention concerns the compounds of formula (I),the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n is zero, 1, 2, 3, 4, 5 or 6; X is CH2 or O; R and R each independently are hydrogen, C1-6alkyl, C1-6alkylcarbonyl, halomethylcarbonyl or C1-6alkyl substituted with hydroxy, C1-6alkyloxy, carboxyl, C1-6alkylcarbonyloxy, C1-6alkyloxycarbonyl or aryl; or R and R taken together with the nitrogen atom to which they are attached may form a morpholinyl ring or an optionally substituted heterocycle; R and R are both halogen; or R is halogen and R is hydrogen; or R is hydrogen and R is halogen; and aryl is phenyl or phenyl substituted with 1, 2 or 3 substituents selected from halo, hydroxy, C1-6alkyl and halomethyl. The compounds of formula (I) may be used as therapeutic agents.
-
公开(公告)号:DE69812668T2
公开(公告)日:2004-01-29
申请号:DE69812668
申请日:1998-10-06
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: ANDRES-GIL JOSE IGNACIO , FERNANDEZ-GADEA FRANCISCO JAVI , GIL-LOPETEGUI PILAR , DIAZ-MARTINEZ ADOLFO
IPC: A61K31/34 , A61K31/343 , A61K31/4427 , A61K31/443 , A61K31/445 , A61K31/4525 , A61K31/495 , A61K31/496 , A61K31/535 , A61K31/5377 , A61K31/55 , A61P25/00 , A61P25/06 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/30 , C07D307/93 , C07D401/06 , C07D405/06 , C07D493/04
Abstract: This invention concerns the compounds of formula (I),the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n is zero, 1, 2, 3, 4, 5 or 6; X is CH2 or O; R and R each independently are hydrogen, C1-6alkyl, C1-6alkylcarbonyl, halomethylcarbonyl or C1-6alkyl substituted with hydroxy, C1-6alkyloxy, carboxyl, C1-6alkylcarbonyloxy, C1-6alkyloxycarbonyl or aryl; or R and R taken together with the nitrogen atom to which they are attached may form a morpholinyl ring or an optionally substituted heterocycle; R and R are both halogen; or R is halogen and R is hydrogen; or R is hydrogen and R is halogen; and aryl is phenyl or phenyl substituted with 1, 2 or 3 substituents selected from halo, hydroxy, C1-6alkyl and halomethyl. The compounds of formula (I) may be used as therapeutic agents.
-
公开(公告)号:PT892793E
公开(公告)日:2003-08-29
申请号:PT97920662
申请日:1997-04-09
Applicant: JANSSEN PHARMACEUTICA NV
IPC: A61K31/00 , A61K31/34 , A61K31/343 , A61K31/4025 , A61K31/4035 , A61K31/443 , A61K31/445 , A61K31/4465 , A61K31/4523 , A61K31/4525 , A61K31/495 , A61K31/496 , A61K31/535 , A61K31/5375 , A61K31/5377 , A61K31/55 , A61P1/00 , A61P1/14 , A61P9/00 , A61P9/02 , A61P25/06 , A61P25/18 , A61P25/22 , A61P25/24 , A61P25/30 , C07D307/93 , C07D405/02 , C07D405/06 , C07D491/048 , C07D493/04 , C07D493/10 , C07D495/04
Abstract: PCT No. PCT/EP97/01829 Sec. 371 Date Oct. 6, 1998 Sec. 102(e) Date Oct. 6, 1998 PCT Filed Apr. 9, 1997 PCT Pub. No. WO97/38991 PCT Pub. Date Oct. 23, 1997This invention concerns the compounds of formula (I), the N-oxide forms, the pharmaceutically acceptable addition salts and the stereoisomeric forms thereof, wherein n is zero to 6; p and q are zero to 4; r is zero to 5; R1 and R2 each independently are hydrogen; optionally substituted C1-6alkyl; C1-6alkylcarbonyl; halomethylcarbonyl; or R1 and R2 taken together with the nitrogen atom to which they are attached may form a morpholinyl ring or an optionally substituted heterocycle; each R3 and R4 independently are halo, cyano, hydroxy, halomethyl, halomethoxy, carboxyl, nitro, amino, mono- or di(C1-6alkyl)amino, C1-6alkylcarbonylamino, aminosulfonyl, mono- or di(C1-6alkyl)aminosulfonyl, C1-6alkyl, C1-6alkyloxy, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl; each R5 independently is C1-6alkyl, cyano or halomethyl; X is CR6R7, NR8, O, S, S(=O) or S(=O)2; aryl is optionally substituted phenyl; provided that the compound is other than (+/-)-3,3a,8,12b-tetrahydro-N-methyl-2H-dibenzo[3,4:6,7]-cyclohepta[1,2-b]-furan-2-methanamine oxalic acid. The compounds of formula (I) may be used as therapeutic agents in the treatment or the prevention of CNS disorders, cardiovascular disorders or gastrointestinal disorders.
-
公开(公告)号:SK283400B6
公开(公告)日:2003-07-01
申请号:SK141898
申请日:1997-04-09
Applicant: JANSSEN PHARMACEUTICA NV
IPC: A61K31/00 , A61K31/34 , A61K31/343 , A61K31/4025 , A61K31/4035 , A61K31/443 , A61K31/445 , A61K31/4465 , A61K31/4523 , A61K31/4525 , A61K31/495 , A61K31/496 , A61K31/535 , A61K31/5375 , A61K31/5377 , A61K31/55 , A61P1/00 , A61P1/14 , A61P9/00 , A61P9/02 , A61P25/06 , A61P25/18 , A61P25/22 , A61P25/24 , A61P25/30 , C07D307/93 , C07D405/02 , C07D405/06 , C07D491/048 , C07D493/04 , C07D493/10 , C07D495/04 , C07D307/94
Abstract: This invention concerns the compounds of formula (I), the N-oxide forms, the pharmaceutically acceptable addition salts and the stereoisomeric forms thereof, wherein n is zero to 6; p and q are zero to 4; r is zero to 5; R1 and R2 each independently are hydrogen; optionally substituted C1-6alkyl; C1-6alkylcarbonyl; halomethylcarbonyl; or R1 and R2 taken together with the nitrogen atom to which they are attached may form a morpholinyl ring or an optionally substituted heterocycle; each R3 and R4 independently are halo, cyano, hydroxy, halomethyl, halomethoxy, carboxyl, nitro, amino, mono- or di(C1-6alkyl)amino, C1-6alkylcarbonylamino, aminosulfonyl, mono- or di(C1-6alkyl)aminosulfonyl, C1-6alkyl, C1-6alkyloxy, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl; each R5 independently is C1-6alkyl, cyano or halomethyl; X is CR6R7, NR8, O, S, S(=O) or S(=O)2; aryl is optionally substituted phenyl; provided that the compound is other than (U)-3,3a,8,12b-tetrahydro-N-methyl-2H- dibenzo[3,4:6,7]-cyclohepta[1,2-b]-furan-2-methanamine oxalic acid. The compounds of formula (I) may be used as therapeutic agents in the treatment or the prevention of CNS disorders, cardiovascular disorders or gastrointestinal disorders.
-
公开(公告)号:AT236893T
公开(公告)日:2003-04-15
申请号:AT97920662
申请日:1997-04-09
Applicant: JANSSEN PHARMACEUTICA NV
IPC: A61K31/00 , A61K31/34 , A61K31/343 , A61K31/4025 , A61K31/4035 , A61K31/443 , A61K31/445 , A61K31/4465 , A61K31/4523 , A61K31/4525 , A61K31/495 , A61K31/496 , A61K31/535 , A61K31/5375 , A61K31/5377 , A61K31/55 , A61P1/00 , A61P1/14 , A61P9/00 , A61P9/02 , A61P25/06 , A61P25/18 , A61P25/22 , A61P25/24 , A61P25/30 , C07D307/93 , C07D405/02 , C07D405/06 , C07D491/048 , C07D493/04 , C07D493/10 , C07D495/04 , C07D313/00
Abstract: PCT No. PCT/EP97/01829 Sec. 371 Date Oct. 6, 1998 Sec. 102(e) Date Oct. 6, 1998 PCT Filed Apr. 9, 1997 PCT Pub. No. WO97/38991 PCT Pub. Date Oct. 23, 1997This invention concerns the compounds of formula (I), the N-oxide forms, the pharmaceutically acceptable addition salts and the stereoisomeric forms thereof, wherein n is zero to 6; p and q are zero to 4; r is zero to 5; R1 and R2 each independently are hydrogen; optionally substituted C1-6alkyl; C1-6alkylcarbonyl; halomethylcarbonyl; or R1 and R2 taken together with the nitrogen atom to which they are attached may form a morpholinyl ring or an optionally substituted heterocycle; each R3 and R4 independently are halo, cyano, hydroxy, halomethyl, halomethoxy, carboxyl, nitro, amino, mono- or di(C1-6alkyl)amino, C1-6alkylcarbonylamino, aminosulfonyl, mono- or di(C1-6alkyl)aminosulfonyl, C1-6alkyl, C1-6alkyloxy, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl; each R5 independently is C1-6alkyl, cyano or halomethyl; X is CR6R7, NR8, O, S, S(=O) or S(=O)2; aryl is optionally substituted phenyl; provided that the compound is other than (+/-)-3,3a,8,12b-tetrahydro-N-methyl-2H-dibenzo[3,4:6,7]-cyclohepta[1,2-b]-furan-2-methanamine oxalic acid. The compounds of formula (I) may be used as therapeutic agents in the treatment or the prevention of CNS disorders, cardiovascular disorders or gastrointestinal disorders.
-
公开(公告)号:AT235479T
公开(公告)日:2003-04-15
申请号:AT98950107
申请日:1998-10-06
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: ANDRES-GIL JOSE IGNACIO , FERNANDEZ-GADEA FRANCISCO JAVI , GIL-LOPETEGUI PILAR , DIAZ-MARTINEZ ADOLFO
IPC: A61K31/34 , A61K31/343 , A61K31/4427 , A61K31/443 , A61K31/445 , A61K31/4525 , A61K31/495 , A61K31/496 , A61K31/535 , A61K31/5377 , A61K31/55 , A61P25/00 , A61P25/06 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/30 , C07D307/93 , C07D401/06 , C07D405/06 , C07D493/04
Abstract: This invention concerns the compounds of formula (I),the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n is zero, 1, 2, 3, 4, 5 or 6; X is CH2 or O; R and R each independently are hydrogen, C1-6alkyl, C1-6alkylcarbonyl, halomethylcarbonyl or C1-6alkyl substituted with hydroxy, C1-6alkyloxy, carboxyl, C1-6alkylcarbonyloxy, C1-6alkyloxycarbonyl or aryl; or R and R taken together with the nitrogen atom to which they are attached may form a morpholinyl ring or an optionally substituted heterocycle; R and R are both halogen; or R is halogen and R is hydrogen; or R is hydrogen and R is halogen; and aryl is phenyl or phenyl substituted with 1, 2 or 3 substituents selected from halo, hydroxy, C1-6alkyl and halomethyl. The compounds of formula (I) may be used as therapeutic agents.
-
公开(公告)号:HU0003748A2
公开(公告)日:2002-01-28
申请号:HU0003748
申请日:1998-10-06
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: ANDRES-GIL JOSE IGNACIO , DIAZ-MARTINEZ ADOLFO , FERNANDEZ-GADEA FRANCISCO JAVI , GIL-LOPETEGUI PILAR
IPC: A61K31/34 , A61K31/343 , A61K31/4427 , A61K31/443 , A61K31/445 , A61K31/4525 , A61K31/495 , A61K31/496 , A61K31/535 , A61K31/5377 , A61K31/55 , A61P25/00 , A61P25/06 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/30 , C07D307/93 , C07D401/06 , C07D405/06 , C07D493/04
Abstract: This invention concerns the compounds of formula (I),the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n is zero, 1, 2, 3, 4, 5 or 6; X is CH2 or O; R and R each independently are hydrogen, C1-6alkyl, C1-6alkylcarbonyl, halomethylcarbonyl or C1-6alkyl substituted with hydroxy, C1-6alkyloxy, carboxyl, C1-6alkylcarbonyloxy, C1-6alkyloxycarbonyl or aryl; or R and R taken together with the nitrogen atom to which they are attached may form a morpholinyl ring or an optionally substituted heterocycle; R and R are both halogen; or R is halogen and R is hydrogen; or R is hydrogen and R is halogen; and aryl is phenyl or phenyl substituted with 1, 2 or 3 substituents selected from halo, hydroxy, C1-6alkyl and halomethyl. The compounds of formula (I) may be used as therapeutic agents.
-
-
-
-
-
-
-
-
-